
EXCLUSIVE: Shape Therapeutics raises $112M in bid to make RNA editing — and a whole lot else — a reality
Two years after spinning out of CRISPR pioneer Prashant Mali’s lab, Shape Therapeutics has a lot more cash and a slightly new mission.
The company originally launched in 2019 with plans to develop therapies around a new form of gene editing, one they hoped could better address certain diseases than CRISPR or other forms of gene manipulations. That’s still their goal, but CEO Francois Vigneault has added a few others in the meantime.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.